Cannabinoid-mediated antinociception is enhanced in rat osteoarthritic knees

Arthritis and Rheumatism

Volumn 58, Issue 1, 2008, Pages 145-153

  Schuelert, Niklas ^a   McDougall, Jason J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 CHLOROETHANOL; 4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; ARACHIDONYL 2 CHLOROETHYLAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; ENDOCANNABINOID; IODOACETIC ACID; SODIUM DERIVATIVE; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; JOINT MOBILITY; KNEE OSTEOARTHRITIS; MALE; NERVE CELL EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; RAT; SENSORY NERVE; TREATMENT RESPONSE;

AFFERENT PATHWAYS; ANILIDES; ANIMALS; ARACHIDONIC ACIDS; CINNAMATES; KNEE JOINT; MALE; NOCICEPTORS; OSTEOARTHRITIS, KNEE; PAIN; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; TRPV CATION CHANNELS;

EID: 38149076483     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23156     Document Type: Article

References (56)

1. Janusz MJ, Hookfin EB, Heitmeyer SA, Woessner JF, Freemont AJ, Hoyland JA, et al. Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. Osteoarthritis Cartilage 2001;9:751-60.
2. Kalbhen DA. Chemical model of osteoarthritis: a pharmacological evaluation. J Rheumatol 1987;14 Spec No.:130-1.
3. McDougall JJ, Watkins L, Li Z. Vasoactive intestinal peptide (VIP) is a modulator of joint pain in a rat model of osteoarthritis. Pain 2006;123:98-105.
4. Schuelert N, McDougall JJ. Electrophysiological evidence that the vasoactive intestinal peptide receptor antagonist VIP6-28 reduces nociception in an animal model of osteoarthritis. Osteoarthritis Cartilage 2006;14:1155-62.
5. Schaible HG, Schmidt RF. Activation of groups III and IV sensory units in medial articular nerve by local mechanical stimulation of knee joint. J Neurophysiol 1983;49:35-44.
6. Just S, Pawlak M, Heppelmann B. Responses of fine primary afferent nerve fibres innervating the rat knee joint to defined torque. J Neurosci Methods 2000;103:157-62.
7. Schaible HG, Grubb BD. Afferent and spinal mechanisms of joint pain [review]. Pain 1993;55:5-54.
8. Walker JM, Huang SM. Endocannabinoids in pain modulation [review]. Prostaglandins Leukot Essent Fatty Acids 2002;66: 235-42.
9. Rice AS. Cannabinoids and pain [review]. Curr Opin Investig Drugs 2001;2:399-414.
10. Pertwee RG. Cannabinoid receptors and pain [review]. Prog Neurobiol 2001;63:569-611.
11. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors [review]. Pharmacol Ther 1997;74:129-80.
12. Pertwee RG. Pharmacological, physiological and clinical implications of the discovery of cannabinoid receptors [review]. Biochem Soc Trans 1998;26:267-72.
13. Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives [review]. Chem Phys Lipids 2002;121:173-90.
14. Matsuda LA, Lolait SI, Brownstein MI, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4.
15. 2 receptor. Eur J Pharmacol 2000;396:141-9.
16. Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A 1999;96:14136-41.
17. Malan TP Jr, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T, et al. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001;93:239-45.
18. Mackie K, Lai Y, Westenbroek R, Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 1995;15:6552-61.
19. Mackie K, Devane WA, Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol 1993;44:498-503.
20. Howlett AC, Johnson MR, Melvin LS, Milne GM. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol Pharmacol 1988;33:297-302.
21. Ameri A. The effects of cannabinoids on the brain [review]. Prog Neurobiol 1999;58:315-48.
22. Hohmann AG, Briley EM, Herkenham M. Pre- and postsynaptic distribution of cannabinoid and μ opioid receptors in rat spinal cord. Brain Res 1999;822:17-25.
23. Hohmann AG, Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 1999;92:1171-5.
24. Ahluwalia J, Urban L, Capogna M, Bevan S, Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience 2000;100:685-8.
25. Elmes SJ, Winyard LA, Medhurst SJ, Clayton NM, Wilson AW, Kendall DA, et al. Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain 2005;118:327-35.
26. 35S]GTPγS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur J Neurosci 2000;12:2079-86.
27. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999;400:452-7.
28. Smart D, Jerman JC. Anandamide: an endogenous activator of the vanilloid receptor [letter]. Trends Pharmacol Sci 2000;21:134.
29. Baker CL, McDougall JJ. The cannabinomimetic arachidonyl-2- chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints. Br J Pharmacol 2004;142:1361-7.
30. Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms [review]. Pharmacol Rev 1999;51:159-212.
31. Szallasi A. Vanilloid (capsaicin) receptors in health and disease [review]. Am J Clin Pathol 2002;118:110-21.
32. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389:816-24.
33. Costa B, Giagnoni G, Franke C, Trovato AE, Colleoni M. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 2004;143:247-50.
34. Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000;405:183-7.
35. Amaya F, Shimosato G, Kawasaki Y, Hashimoto S, Tanaka Y, Ji RR, et al. Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonist. Pain 2006;124:175-83.
36. McDougall JJ, Pawlak M, Hanesch U, Schmidt RF. Peripheral modulation of rat knee joint afferent mechanosensitivity by nociceptin/orphanin FQ. Neurosci Lett 2000;288:123-6.
37. Bove SE, Calcaterra SL, Brooker RM, Huber CM, Guzman RE, Juneau PL, et al. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage 2003;11:821-30.
38. Guingamp C, Gegout-Pottie P, Philippe L, Terlain B, Netter P, Gillet P. Mono-iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry. Arthritis Rheum 1997;40:1670-9.
39. Hillard CJ, Manna S, Greenberg MJ, DiCamelli R, Ross RA, Stevenson LA, et al. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 1999;289:1427-33.
40. Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview [review]. Int J Obes (Lond) 2006;30 Suppl 1:S13-8.
41. Rami HK, Thompson M, Wyman P, Jerman JC, Egerton J, Brough S, et al. Discovery of small molecule antagonists of TRPV1. Bioorg Med Chem Lett 2004;14:3631-4.
42. Schaible HG, Schmidt RF. Effects of an experimental arthritis on the sensory properties of fine articular afferent units. J Neurophysiol 1985;54:1109-22.
43. Schaible HG, Schmidt RF. Time course of mechanosensitivity changes in articular afferents during a developing experimental arthritis. J Neurophysiol 1988;60:2180-95.
44. 2 cannabinoid receptors [review]. Chem Phys Lipids 2002;121: 191-200.
45. 2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol 2007;150:153-63.
46. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998;394:277-81.
47. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB, receptors. Pain 1998;75:111-9.
48. 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001;92:91-100.
49. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 2000;129:227-30.
50. Gunthorpe MJ, Rami HK, Jerman JC, Smart D, Gill CH, Soffin EM, et al. Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist [published erratum appears in Neuropharmacology 2004;46:905]. Neuropharmacology 2004;46:133-49.
51. Varga A, Nemeth J, Szabo A, McDougall JJ, Zhang C, Elekes K, et al. Effects of the novel TRPV1 receptor antagonist SB366791 in vitro and in vivo in the rat. Neurosci Lett 2005;385:137-42.
52. Szolcsanyi J. Capsaicin receptors as target molecules on nociceptors for development of novel analgesic agents. In: Keri G, Toth I, editors. Molecular pathomechanisms and new trends in drug research. London: Taylor & Francis; 2002. p. 319-33.
53. Lizanecz E, Bagi Z, Pasztor ET, Papp Z, Edes I, Kedei N, et al. Phosphorylation-dependent desensitization by anandamide of vanilloid receptor-1 (TRPV1) function in rat skeletal muscle arterioles and in Chinese hamster ovary cells expressing TRPV1. Mol Pharmacol 2006;69:1015-23.
54. Varga A, Bolcskei K, Szoke E, Almasi R, Czeh G, Szolcsanyi J, et al. Relative roles of protein kinase A and protein kinase C in modulation of transient receptor potential vanilloid type 1 receptor responsiveness in rat sensory neurons in vitro and peripheral nociceptors in vivo. Neuroscience 2006;140:645-57.
55. Gutierrez T, Farthing JN, Zvonok AM, Makriyannis A, Hohmann AG. Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol 2007;150:153-63.
56. Suplita RL II, Gutierrez T, Fegley D, Piomelli D, Hohmann AG. Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. Neuropharmacology 2006;50: 372-9.